Lataa...
Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and complete in...
Tallennettuna:
| Julkaisussa: | Clin Case Rep |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8077291/ https://ncbi.nlm.nih.gov/pubmed/33936613 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3900 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|